李双;李明珠;丛青;杨帆;刘红;李克敏;宋坤;尹如铁;王新宇;张国楠;隋龙;刘继红;孔北华;谢幸;魏丽惠;马丁;

• 1:中国优生科学协会阴道镜和宫颈病理学分会
• 2:中华医学会妇科肿瘤学分会
• 3:华中科技大学同济医学院附属同济医院
• 4:北京大学人民医院

摘要(Abstract)：

人乳头瘤病毒(HPV)疫苗接种是预防HPV感染和相关疾病的有效方法,是防控HPV感染相关疾病的一级预防措施。低龄人群接种HPV疫苗的效果优于高龄人群,性暴露前接种免疫效果最佳。HPV疫苗不仅适用于一般普通人群,同样推荐用于高危、特殊人群。对具有遗传易感、高危生活方式和人类免疫缺陷病毒感染的适龄女性应优先推荐接种HPV疫苗。不论是否有HPV感染、细胞学是否异常的适龄女性均可接种HPV疫苗。近期有妊娠计划和妊娠期、哺乳期女性不宜接种HPV疫苗。接种HPV疫苗后仍应进行子宫颈癌筛查。

关键词(KeyWords)： 人乳头瘤病毒;疫苗;临床应用;高危;特殊人群

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金重点项目(No:81630060);国家自然科学基金面上项目(No:81974410);; 妇幼健康研究会研究项目(No:2018AMCHS008);; 浙江省科技厅重点研发项目(No:2020C03025);; 上海市科学技术委员会科研计划项目(No:18411963600)

作者(Authors): 李双;李明珠;丛青;杨帆;刘红;李克敏;宋坤;尹如铁;王新宇;张国楠;隋龙;刘继红;孔北华;谢幸;魏丽惠;马丁;

DOI: 10.13283/j.cnki.xdfckjz.2021.02.001

参考文献(References)：

• [1] Mcbride AA.Oncogenic human papillomaviruses[J].Philos Trans R Soc Lond B Biol Sci,2017,372(1732):20160273
• [2] Chesson HW,Dunne EF,Hariri S,et al.The estimated lifetime probability of acquiring human papillomavirus in the United States[J].Sex Transm Dis,2014,41(11):660-664
• [3] Gargano J,Meites E,Watson M,et al.Manual for the Surveillance of Vaccine-Preventable Diseases:Human Papillomavirus[OL].(2020-04-28)[2020-11-28].https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html
• [4] World Health Organization.Human papillomavirus vaccines:WHO position paper,May 2017-Recommendations[J].Vaccine,2017,35(43):5753-5755
• [5] Bruni L,Diaz M,Castellsague X,et al.Cervical human papillomavirus prevalence in 5 continents:meta-analysis of 1 million women with normal cytological findings[J].J Infect Dis,2010,202(12):1789-1799
• [6] Guan P,Howell-jones R,Li N,et al.Human papillomavirus types in 115,789 HPV-positive women:a meta-analysis from cervical infection to cancer[J].Int J Cancer,2012,131(10):2349-2359
• [7] No authors listed.Human papillomavirus vaccines:WHO position paper,May 2017[J].Wkly Epidemiol Rec,2017,92(19):241-268
• [8] De Sanjose S,Quint WG,Alemany L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J].Lancet Oncol,2010,11(11):1048-1056
• [9] Wu EQ,Liu B,Cui JF,et al.Prevalence of type-specific human papillomavirus and pap results in Chinese women:a multi-center,population-based cross-sectional study[J].Cancer Causes Control,2013,24(4):795-803
• [10] Chen W,Zhang X,Molijn A,et al.Human papillomavirus type-distribution in cervical cancer in China:the importance of HPV 16 and 18[J].Cancer Causes Control,2009,20(9):1705-1713
• [11] De MarteL C,Georges D,Bray F,et al.Global burden of cancer attributable to infections in 2018:a worldwide incidence analysis[J].Lancet Glob Health,2020,8(2):e180-e190
• [12] De Martel C,Plummer M,Vignat J,et al.Worldwide burden of cancer attributable to HPV by site,country and HPV type[J].Int J Cancer,2017,141(4):664-670
• [13] Bruni L,Albero G,Serrano B,et al.ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).Human Papillomavirus and Related Diseases in the World[OL].(2019-06-17)[2020-11-25].https://hpvcentre.net/statistics/reports/XWX.pdf?t=1606721151283
• [14] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424
• [15] Bruni L,Albero G,Serrano B,et al.ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).Human Papillomavirus and Related Diseases in China[OL].(2019-06-17)[2020-11-25].https://hpvcentre.net/statistics/reports/CHN.pdf?t=1606722464904
• [16] Giuliano AR,Nyitray AG,Kreimer AR,et al.EUROGIN 2014 roadmap:differences in human papillomavirus infection natural history,transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection[J].Int J Cancer,2015,136(12):2752-2760
• [17] Centers for Disease Control and Prevertion.Human Papillomavirus (HPV) Infection[OL].(2015-06-04)[2020-11-25].https://www.cdc.gov/std/tg2015/hpv.htm
• [18] Colombara DV,Wang SM.The impact of HPV vaccination delays in China:lessons from HBV control programs[J].Vaccine,2013,31(38):4057-4059
• [19] Zeng Z,Yang H,Li Z,et al.Prevalence and genotype distribution of HPV infection in China:analysis of 51,345 HPV genotyping results from China's largest CAP certified laboratory[J].J Cancer,2016,7(9):1037-1043
• [20] Wei L,Xie X,Liu J,et al.Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women:A randomized,placebo-controlled trial with 78-month follow-up[J].Vaccine,2019,37(27):3617-3624
• [21] Zhu FC,Li J,Hu YM,et al.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J].Hum Vaccin Immunother,2014,10(7):1795-1806
• [22] Li R,Li Y,Radley D,et al.Safety and immunogenicity of a vaccine targeting human papillomavirus types 6,11,16 and 18:a randomized,double-blind,placebo-controlled trial in Chinese males and females[J].Vaccine,2012,30(28):4284-4291
• [23] Hu YM,Guo M,Li CG,et al.Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs.3 doses in young women[J].Sci China Life Sci,2020,63(4):582-591
• [24] Van Damme P,Meijer CJLM,Kieninger D,et al.A phase Ⅲ clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J].Vaccine,2016,34(35):4205-4212
• [25] Joura EA,Kyrgiou M,Bosch FX,et al.Human papillo?倕mavirus vaccination:The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy[J].Eur J Cancer,2019,116:21-26
• [26] Barr E,Gause CK,Bautista OM,et al.Impact of a prophylactic quadrivalent human papillomavirus (types 6,11,16,18) L1 virus-like particle vaccine in a sexually active population of North American women[J].Am J Obstet Gynecol,2008,198(3):261.e1-e11
• [27] Australian Government Department of Health.Human papillomavirus (HPV) immunization service[OL].(2019-09-26)[2020-11-25].https://www.health.gov.au/health-topics/immunisation/immunisation-services/human-papillomavirus-hpv-immunisation
• [28] Olsson SE,Kjaer SK,Sigurdsson K,et al.Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection[J].Hum Vaccin,2009,5(10):696-704
• [29] Zhu FC,Hu SY,Hong Y,et al.Efficacy,immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years:End-of-study results from a phase Ⅱ/Ⅲ,randomised,controlled trial[J].Cancer Med,2019,8(14):6195-6211
• [30] Qiao YL,Wu T,Li RC,et al.Efficacy,Safety,and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine:An Interim Analysis of a Randomized Clinical Trial[J].J Natl Cancer Inst,2020,112(2):145-153
• [31] FUTURE Ⅱ Study Group.Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].N Engl J Med,2007,356(19):1915-1927
• [32] Lei J,Ploner A,Elfstrom KM,et al.HPV vaccination and the risk of invasive cervical cancer[J].N Engl J Med,2020,383(14):1340-1348
• [33] Joura EA,Giuliano AR,Iversen OE,et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med,2015,372(8):711-723
• [34] Garland SM,Pitisuttithum P,Ngan HYS,et al.Efficacy,immunogenicity,and safety of a 9-valent human papillomavirus vaccine:subgroup analysis of participants from Asian countries[J].J Infect Dis,2018,218(1):95-108
• [35] Ruiz-sternberg AM,Moreira ED jr,Restrepo JA,et al.Efficacy,immunogenicity,and safety of a 9-valent human papillomavirus vaccine in Latin American girls,boys,and young women[J].Papillomavirus Res,2018,5:63-74
• [36] International Federation of Gynecology & Obstetrics.Global Guidance For Cervical Cancer Prevention and Control (2009)[OL].[2020-11-25].https://www.figo.org/sites/default/files/2020-07/Control_English_version.pdf
• [37] 中华预防医学会疫苗与免疫分会.子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识(简版)[J].中华预防医学杂志,2019,53(12):1218-1235
• [38] U.S.Food & Drug Administration.FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old[OL].(2018-10-05)[2020-11-25].https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old
• [39] Meites E,Szilagyi PG,Chesson HW,et al.Human Papillomavirus Vaccination for Adults:Updated Recom mendations of the Advisory Committee on Immunization Practices[J].MMWR Morb Mortal Wkly Rep,2019,68(32):698-702
• [40] Centers for Disease Control and Prevertion.Vaccines at 11 to 12 Years[OL].(2020-02-25)[2020-11-25].https://www.cdc.gov/vaccines/parents/by-age/years-11-12.html
• [41] Immunization Expert Work Group,Committee on Adolescent Health Care.Committee Opinion No.704:Human Papillomavirus Vaccination[J].Obstet Gynecol,2017,129(6):e173-e178
• [42] Human papillomavirus vaccine:Canadian Immunization Guide[OL].[2020-11-25].https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html
• [43] Aslow D,Andrews KS,Manassaram-baptiste D,et al.Human papillomavirus vaccination 2020 guideline update:American Cancer Society guideline adaptation[J].CA Cancer J Clin,2020,70(4):274-280
• [44] Zhao FH,Tiggelaar SM,Hu SY,et al.A multi-center survey of age of sexual debut and sexual behavior in Chinese women:suggestions for optimal age of human papillomavirus vaccination in China[J].Cancer Epidemiol,2012,36(4):384-390
• [45] Li K,Li Q,Song L,et al.The distribution and prevalence of human papillomavirus in women in China's mainland[J].Cancer,2019,125(7):1030-1037
• [46] Zhao FH,Lewkowitz AK,Hu SY,et al.Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China:a pooled analysis of 17 population-based studies[J].Int J Cancer,2012,131(12):2929-2938
• [47] Viscidi RP,Schiffman M,Hildesheim A,et al.Seroreactivity to human papillomavirus (HPV) types 16,18,or 31 and risk of subsequent HPV infection:results from a population-based study in Costa Rica[J].Cancer Epidemiol Biomarkers Prev,2004,13(2):324-327
• [48] Castellsague X,Munoz N,Pitisuttithum P,et al.End-of-study safety,immunogenicity,and efficacy of quadrivalent HPV (types 6,11,16,18) recombinant vaccine in adult women 24-45 years of age[J].Br J Cancer,2011,105(1):28-37
• [49] Giuliano AR,Joura EA,Garland SM,et al.Nine-valent HPV vaccine efficacy against related diseases and definitive therapy:comparison with historic placebo popul?倕ation[J].Gynecol Oncol,2019,154(1):110-117
• [50] Huh WK,Joura EA,Giuliano AR,et al.Final efficacy,immunogenicity,and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years:a randomised,double-blind trial[J].Lancet,2017,390(10108):2143-2159
• [51] Panagiotou OA,Befano BL,Gonzalez P,et al.Effect of bivalent human papillomavirus vaccination on pregnancy outcomes:long term observational follow-up in the Costa Rica HPV Vaccine Trial[J].BMJ,2015,351:h4358
• [52] Angelo MG,Zima J,Tavares DA Silva F,et al.Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine:more than 4 years of experience[J].Pharmacoepidemiol Drug Saf,2014,23(5):456-465
• [53] Centers for Disease Control and Prevention (CDC).FDA licensure of bivalent human papillomavirus vaccine (HPV2,Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)[J].MMWR Morb Mortal Wkly Rep,2010,59(20):626-629
• [54] Garland SM,Ault KA,Gall SA,et al.Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine:a combined analysis of five randomized controlled trials[J].Obstet Gynecol,2009,114(6):1179-1188
• [55] Scheller NM,Pasternak B,Molgaard-nielsen D,et al.Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes[J].N Engl J Med,2017,376(13):1223-1233
• [56] Landazabal CS,Moro PL,Lewis P,et al.Safety of 9-valent human papillomavirus vaccine administration among pregnant women:Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS),2014-2017[J].Vaccine,2019,37(9):1229-1234
• [57] Tan J,Xiong YQ,He Q,et al.Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion:a systematic review and meta-analysis[J].BMC Pregnancy Childbirth,2019,19(1):302
• [58] Markowitz LE,Dunne EF,Saraiya M,et al.Human papillomavirus vaccination:recommendations of the Advisory Committee on Immunization Practices (ACIP)[J].MMWR Recomm Rep,2014,63(RR-05):1-30
• [59] Min KJ,Kwon SH,Kim K,et al.Clinical guideline for 9-valent HPV vaccine:Korean Society of Gynecologic Oncology Guideline[J].J Gynecol Oncol,2019,30(2):456
• [60] Kang WD,Choi HS,Kim SM.Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3) [J].Gynecol Oncol,2013,130(2):264-268
• [61] Garland SM,Paavonen J,Jaisamrarn U,et al.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy:Post-hoc analysis from a randomized controlled trial[J].Int J Cancer,2016,139(12):2812-2826
• [62] Ghelardi A,Parazzini F,Martella F,et al.SPERANZA project:HPV vaccination after treatment for CIN2[J].Gynecol Oncol,2018,151(2):229-234
• [63] Pieralli A,Bianchi C,Auzzi N,et al.Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease[J].Arch Gynecol Obstet,2018,298(6):1205-1210
• [64] Swedish KA,Factor SH,Goldstone SE.Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men:a nonconcurrent cohort study[J].Clin Infect Dis,2012,54(7):891-898
• [65] Deshmukh AA,Chhatwal J,Chiao EY,et al.Long-term outcomes of adding HPV vaccine to the anal Intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men[J].Clin Infect Dis,2015,61(10):1527-1535
• [66] Markowitz LE,Dunne EF,Saraiya M,et al.Human Papillomavirus Vaccination:Recommendations of the Advisory Committee on Immunization Practices (ACIP)[OL].(2014-08-29)[2020-11-25].https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm
• [67] Hemminki K,Dong C,Vaittinen P.Familial risks in cervical cancer:is there a hereditary component?[J].Int J Cancer,1999,82(6):775-781
• [68] Magnusson PK,Lichtenstein P,Gyllensten UB.Heritability of cervical tumours[J].Int J Cancer,2000,88(5):698-701
• [69] Chen D,Juko-Pecirep I,Hammer J,et al.Genome-wide association study of susceptibility loci for cervical cancer[J].J Natl Cancer Inst,2013,105(9):624-633
• [70] Shi Y,Li L,Hu Z,et al.A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12[J].Nat Genet,2013,45(8):918-922
• [71] Tovar JM,Bazaldua OV,Vargas L,et al.Human papillomavirus,cervical cancer,and the vaccines[J].Postgrad Med,2008,120(2):79-84
• [72] Moscicki AB.Impact of HPV infection in adolescent populations[J].J Adolesc Health,2005,37(6 Suppl):S3-S9
• [73] Zhao FH,Forman MR,Belinson J,et al.Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China[J].Int J Cancer,2006,118(2):442-448
• [74] How CD4 Counts Help Treat HIV and AIDS[OL].(2019-06-23)[2020-11-26].https://www.webmd.com/hiv-aids/cd4-count-what-does-it-mean
• [75] Denny L,Hendricks B,Gordon C,et al.Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa:a partially-blind randomised placebo-controlled study[J].Vaccine,2013,31(48):5745-5753
• [76] Kojic EM,Kang M,Cespedes MS,et al.Immun?倕ogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women[J].Clin Infect Dis,2014,59(1):127-135
• [77] Mcclymont E,Lee M,Raboud J,et al.The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus[J].Clin Infect Dis,2019,68(5):788-794
• [78] Mok CC,Ho LY,Fong LS,et al.Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus:a case-control study[J].Ann Rheum Dis,2013,72(5):659-664
• [79] Nelson DR,Neu AM,Abraham A,et al.Immunogenicity of human papillomavirus recombinant vaccine in children with CKD[J].Clin J Am Soc Nephrol,2016,11(5):776-784
• [80] Praditpornsilpa K,Kingwatanakul P,Deekajorndej T,et al.Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV,V and VD[J].Nephrol Dial Transplant,2017,32(1):132-136
• [81] Reinholdt K,Thomsen LT,Dehlendorff C,et al.Human papillomavirus-related anogenital premalignancies and cancer in renal transplant recipients:A Danish nationwide,registry-based cohort study[J].Int J Cancer,2020,146(9):2413-2422
• [82] Kumar D,Unger ER,Panicker G,et al.Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients[J].Am J Transplant,2013,13(9):2411-2417
• [83] CIOMS Working Groups.Guidelines for Preparing Core Clinical-Safety Information on Drugs[OL].[2020-11-26].https://cioms.ch/wp-content/uploads/2018/03/Guidelines-for-Preparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMS-Working-Group-Ⅲ-and-Ⅴ.pdf
• [84] Reiter PL,Brewer NT,Gottlieb SL,et al.How much will it hurt?HPV vaccine side effects and influence on completion of the three-dose regimen[J].Vaccine,2009,27(49):6840-6844
• [85] Einstein MH,Baron M,Levin MJ,et al.Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years[J].Hum Vaccin,2009,5(10):705-719
• [86] Einstein MH,Baron M,Levin MJ,et al.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine:follow-up from months 12-24 in a Phase Ⅲ randomized study of healthy women aged 18-45 years[J].Hum Vaccin,2011,7(12):1343-1358
• [87] Zhu FC,Hu SY,Hong Y,et al.Efficacy,immunogenicity,and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years:event-triggered analysis of a randomized controlled trial[J].Cancer Med,2017,6(1):12-25
• [88] Chen W,Zhao Y,Xie X,et al.Safety of a quadrivalent human papillomavirus vaccine in a Phase 3,randomized,double-blind,placebo-controlled clinical trial among Chinese women during 90 months of follow-up[J].Vaccine,2019,37(6):889-897
• [89] Moreira ED Jr,Block SL,Ferris D,et al.Safety profile of the 9-valent HPV vaccine:a combined analysis of 7 phase Ⅲ clinical trials[J].Pediatrics,2016,138(2):e20154387
• [90] Lu B,Kumar A,Castellsague X,et al.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women:a systematic review & meta-analysis[J].BMC Infect Dis,2011,11:13
• [91] Yih WK,Greene SK,Zichittella L,et al.Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females[J].Vaccine,2016,34(1):172-178
• [92] Centers for Disease Control and Prevertion.HPV Vaccine Safety and Effectiveness Data[OL].(2019-11-15)[2020-11-26].https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html